ID
28852
Beskrivning
Study ID: 100723 Clinical Study ID: AXR100723 Study Title: A 24 Week Randomized, Double-blind, Double-dummy, Multicenter Study to Compare the Efficacy of Formulation X and AVANDIA™ (8mg OD) in Subjects with Type 2 Diabetes Mellitus Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 4 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia; Avandia XR; Avandia XR,Rosiglitazone XR,Avandia; Rosiglitazone XR Study Indication: Diabetes Mellitus, Type 2 Documentation part: Additional Forms - Investigational Product
Nyckelord
Versioner (1)
- 2018-02-08 2018-02-08 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
8 februari 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Efficacy of Formulation X and AVANDIA in Subjects with Type 2 Diabetes Mellitus 100723
Additional Forms - Investigational Product
- StudyEvent: ODM
Similar models
Additional Forms - Investigational Product
- StudyEvent: ODM
C0600091 (UMLS CUI [1,2])
C0180098 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,3])
C0332307 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,2])
C0013072 (UMLS CUI [1,3])
C0808070 (UMLS CUI [1,2])
C0806020 (UMLS CUI [1,2])